A detailed history of Schroder Investment Management Group transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Schroder Investment Management Group holds 515,297 shares of SUPN stock, worth $18.6 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
515,297
Previous 508,097 1.42%
Holding current value
$18.6 Million
Previous $13.6 Million 18.21%
% of portfolio
0.02%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$25.77 - $35.16 $185,544 - $253,151
7,200 Added 1.42%
515,297 $16.1 Million
Q2 2024

Aug 12, 2024

BUY
$25.99 - $33.85 $3.91 Million - $5.09 Million
150,416 Added 42.05%
508,097 $13.6 Million
Q1 2024

May 14, 2024

SELL
$27.11 - $35.17 $5 Million - $6.48 Million
-184,292 Reduced 34.0%
357,681 $12.2 Million
Q4 2023

Feb 13, 2024

BUY
$22.72 - $29.68 $12.3 Million - $16.1 Million
541,973 New
541,973 $15.7 Million
Q3 2020

Nov 13, 2020

SELL
$20.2 - $25.05 $27,472 - $34,068
-1,360 Closed
0 $0
Q2 2020

Aug 13, 2020

SELL
$17.09 - $24.89 $186,281 - $271,301
-10,900 Reduced 88.91%
1,360 $32,000
Q1 2020

May 15, 2020

SELL
$14.45 - $24.69 $12,730 - $21,751
-881 Reduced 6.7%
12,260 $224,000
Q4 2019

Feb 11, 2020

BUY
$19.93 - $29.13 $261,900 - $382,797
13,141 New
13,141 $312,000
Q3 2018

Nov 13, 2018

SELL
$42.7 - $56.55 $655,146 - $867,646
-15,343 Closed
0 $0
Q2 2018

Aug 13, 2018

BUY
$44.1 - $59.85 $3,351 - $4,548
76 Added 0.5%
15,343 $895,000
Q1 2018

May 11, 2018

BUY
$37.15 - $46.9 $61,037 - $77,056
1,643 Added 12.06%
15,267 $699,000
Q4 2017

Feb 09, 2018

BUY
$36.4 - $42.6 $187,824 - $219,816
5,160 Added 60.96%
13,624 $543,000
Q3 2017

Nov 09, 2017

BUY
$36.75 - $49.65 $311,052 - $420,237
8,464
8,464 $333,000

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.93B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Schroder Investment Management Group Portfolio

Follow Schroder Investment Management Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schroder Investment Management Group, based on Form 13F filings with the SEC.

News

Stay updated on Schroder Investment Management Group with notifications on news.